NCT07158346

Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of CT-L03 in Healthy Volunteers

A Randomized, Open, Single-dose, Crossover-design, Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of CT-L03 in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 49 (actual)
• Sponsor: Celltrion · Industry
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a randomized, open, single-dose, crossover-design, phase I study to evaluate the pharmacokinetics and safety after co-administration of L03RD1 and L03RD2 or administration of CT-L03 in healthy volunteers.

Conditions

• Type 2 Diabetes Mellitus (T2DM)

Interventions

Type	Name	Description
DRUG	L03RD1	1 tablet of L03RD1
DRUG	L03RD2	2 tablets of L03RD2
DRUG	CT-L03	1 tablet of CT-L03

Timeline

• Start date: 2025-08-18
• Primary completion: 2025-10-03
• Completion: 2025-10-23
• First posted: 2025-09-05
• Last updated: 2025-11-21

Locations

1 site across 1 country: South Korea